Skip to main content
CRSP
NASDAQ Life Sciences

CRISPR Therapeutics Reports Positive Clinical Data for CTX310 and Autoimmune CAR-T Zugo-cel, Advances Pipeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$54.3
Mkt Cap
$5.375B
52W Low
$30.04
52W High
$78.48
52W Position info
81% above low
Off High info
31% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CRSP sits 81% above its 52-week low of $30.04.

Summary

CRISPR Therapeutics provided a comprehensive pipeline update, highlighting positive Phase 1 data for CTX310 and early encouraging results for zugo-cel in autoimmune diseases, alongside advancements in other gene editing and regenerative medicine programs.


Key Events · Product Development and Regulatory · CRSP

  • CTX310 Advances to Phase 1b

    Positive Phase 1 data for CTX310, targeting ANGPTL3, demonstrated deep and durable reductions of triglycerides and low-density lipoprotein, leading to its advancement into Phase 1b clinical trials for severe hypertriglyceridemia and refractory hypercholesterolemia.

  • Zugo-cel Shows Promising Autoimmune Data

    Early Phase 1 clinical trials for zugocabtagene geleucel (zugo-cel) in autoimmune diseases, including systemic lupus erythematosus (SLE), reported a patient maintaining drug-free clinical remission through month 9 and another sustaining B cell depletion with a SLEDAI-2K score of 0 through month 2.

  • Eli Lilly Collaboration for Zugo-cel

    CRISPR Therapeutics established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel in combination with pirtobrutinib for aggressive B-cell lymphomas, expanding its oncology development.

  • Next-Generation Programs Progress

    The company is advancing CTX321, a next-generation LPA program with approximately two-fold greater preclinical potency, and CTX213, a next-generation regenerative medicine candidate for diabetes, both progressing towards clinical studies.


Analysis · CRSP · Life Sciences

This 8-K filing provides a comprehensive and positive update on CRISPR Therapeutics' diverse pipeline, which is critical for a clinical-stage biotechnology company. The advancement of CTX310 into Phase 1b trials based on positive Phase 1 data for cardiovascular indications, and particularly the encouraging early clinical results for zugo-cel in autoimmune diseases like SLE, are significant milestones. The reported drug-free remission and B cell depletion in SLE patients suggest potential for a transformative therapy. Furthermore, the collaboration with Eli Lilly for zugo-cel in oncology adds strategic value and external validation. The progress of next-generation candidates like CTX321 and CTX213 also indicates a robust and evolving pipeline, reinforcing the company's long-term growth prospects.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRSP was trading at $54.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $30.04 to $78.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRSP - Latest Insights

CRSP
Nov 10, 2026, 1:48 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $38.93 info
Change: -$6.55 (-14%) info
Market Cap: $3.776B info
CRSP
Nov 09, 2026, 9:16 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $50.42
Real-time Price: $38.93 info
Change: -$11.49 (-23%) info
Market Cap: $3.776B info
CRSP
Nov 02, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.98
Real-time Price: $38.93 info
Change: -$11.05 (-22%) info
Market Cap: $3.776B info
CRSP
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $38.93 info
Change: -$10.08 (-21%) info
Market Cap: $3.776B info
CRSP
Nov 02, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $49.01
Real-time Price: $38.93 info
Change: -$10.08 (-21%) info
Market Cap: $3.776B info